Free Trial

Alterity Therapeutics (ATHE) Competitors

Alterity Therapeutics logo
$4.89 +0.06 (+1.24%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$4.95 +0.06 (+1.23%)
As of 10/17/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ATHE vs. APLT, ELDN, THTX, FATE, NVCT, CRDF, MOLN, ANRO, ACOG, and CTOR

Should you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Applied Therapeutics (APLT), Eledon Pharmaceuticals (ELDN), Theratechnologies (THTX), Fate Therapeutics (FATE), Nuvectis Pharma (NVCT), Cardiff Oncology (CRDF), Molecular Partners (MOLN), Alto Neuroscience (ANRO), Alpha Cognition (ACOG), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical products" industry.

Alterity Therapeutics vs. Its Competitors

Alterity Therapeutics (NASDAQ:ATHE) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Alterity Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 145.40%. Applied Therapeutics has a consensus price target of $4.13, indicating a potential upside of 222.27%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Applied Therapeutics is more favorable than Alterity Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alterity Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Applied Therapeutics
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17

Alterity Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500.

2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Alterity Therapeutics' return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alterity TherapeuticsN/A N/A N/A
Applied Therapeutics N/A -354.24%-144.16%

In the previous week, Applied Therapeutics had 3 more articles in the media than Alterity Therapeutics. MarketBeat recorded 4 mentions for Applied Therapeutics and 1 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 1.00 beat Applied Therapeutics' score of 0.32 indicating that Alterity Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Alterity Therapeutics Positive
Applied Therapeutics Neutral

Alterity Therapeutics has higher earnings, but lower revenue than Applied Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alterity TherapeuticsN/AN/A-$7.87MN/AN/A
Applied Therapeutics$460K400.72-$105.62M-$0.45-2.84

Summary

Applied Therapeutics beats Alterity Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Alterity Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATHE vs. The Competition

MetricAlterity TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$43.36M$3.43B$6.20B$10.53B
Dividend YieldN/A2.28%5.70%4.83%
P/E RatioN/A23.1685.7027.13
Price / SalesN/A468.51585.75179.61
Price / CashN/A46.9237.1060.81
Price / Book1.5810.4112.236.52
Net Income-$7.87M-$52.77M$3.33B$276.93M
7 Day Performance13.99%2.31%1.17%1.93%
1 Month Performance9.15%12.59%6.85%2.19%
1 Year Performance288.10%11.18%58.93%34.62%

Alterity Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATHE
Alterity Therapeutics
2.5655 of 5 stars
$4.89
+1.2%
$12.00
+145.4%
+288.1%$43.36MN/A0.0010Positive News
Short Interest ↓
APLT
Applied Therapeutics
3.7617 of 5 stars
$1.11
-3.1%
$4.13
+273.3%
-85.7%$160.57M$460K-2.4830News Coverage
Analyst Forecast
ELDN
Eledon Pharmaceuticals
1.8097 of 5 stars
$2.68
-1.7%
$10.00
+273.8%
+15.8%$159.58MN/A-2.2810News Coverage
Gap Up
THTX
Theratechnologies
N/A$3.42
+0.9%
N/A+157.1%$157.21M$84.38M-17.99140High Trading Volume
FATE
Fate Therapeutics
4.1539 of 5 stars
$1.36
-2.5%
$3.30
+143.5%
-54.5%$156.04M$13.63M-0.93550
NVCT
Nuvectis Pharma
2.584 of 5 stars
$6.13
-1.1%
$15.33
+150.3%
-18.8%$155.82MN/A-5.238News Coverage
CRDF
Cardiff Oncology
2.5455 of 5 stars
$2.25
-0.7%
$10.63
+373.3%
-24.5%$149.29M$680K-2.5820Positive News
MOLN
Molecular Partners
1.4795 of 5 stars
$3.70
-2.5%
$8.00
+116.5%
-22.1%$149.20M$5.65M-1.78180Positive News
Analyst Forecast
ANRO
Alto Neuroscience
2.1733 of 5 stars
$5.49
-6.6%
$9.80
+78.5%
-57.8%$148.67MN/A-2.30N/AGap Down
ACOG
Alpha Cognition
2.322 of 5 stars
$6.99
-0.9%
$20.00
+186.1%
N/A$146.09MN/A-4.37N/AAnalyst Downgrade
Short Interest ↑
CTOR
Citius Oncology
2.0535 of 5 stars
$1.74
+0.6%
$6.00
+244.8%
+37.1%$145.31MN/A0.00N/ANews Coverage

Related Companies and Tools


This page (NASDAQ:ATHE) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners